229 related articles for article (PubMed ID: 25380183)
1. Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma.
Anforth RM; Carlos GR; Scolyer RA; Chou S; Fernandez-Peñas P
Melanoma Res; 2015 Feb; 25(1):91-4. PubMed ID: 25380183
[TBL] [Abstract][Full Text] [Related]
2. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic
Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R
Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198
[No Abstract] [Full Text] [Related]
3. High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib.
Göppner D; Müller J; Krüger S; Franke I; Gollnick H; Quist SR
Acta Derm Venereol; 2014 Sep; 94(5):517-20. PubMed ID: 24531394
[TBL] [Abstract][Full Text] [Related]
4. Detection of cell-free circulating BRAF
Calbet-Llopart N; Potrony M; Tell-Martí G; Carrera C; Barreiro A; Aguilera P; Podlipnik S; Puig S; Malvehy J; Puig-Butillé JA
Br J Dermatol; 2020 Feb; 182(2):382-389. PubMed ID: 31102256
[TBL] [Abstract][Full Text] [Related]
5. The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive mitogen-activated protein kinase pathway activation.
Tan JM; Tom LN; Jagirdar K; Lambie D; Schaider H; Sturm RA; Soyer HP; Stark MS
Br J Dermatol; 2018 Jan; 178(1):191-197. PubMed ID: 28714107
[TBL] [Abstract][Full Text] [Related]
6. Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.
Kakavand H; Crainic O; Lum T; O'Toole SA; Kefford RF; Thompson JF; Wilmott JS; Long GV; Scolyer RA
Pathology; 2014 Apr; 46(3):193-8. PubMed ID: 24614711
[TBL] [Abstract][Full Text] [Related]
7. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
9. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
10. Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo.
Tschandl P; Berghoff AS; Preusser M; Pammer J; Pehamberger H; Kittler H
Br J Dermatol; 2016 Feb; 174(2):364-70. PubMed ID: 26613644
[TBL] [Abstract][Full Text] [Related]
11. Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases.
Alfallouji Y; Spencer A; Calonje E; Perrett CM; Watchorn R; Borysiewicz C; Hodgkinson T; Wasan H; Bunker CB; Sidwell RU
Clin Exp Dermatol; 2022 Oct; 47(10):1857-1858. PubMed ID: 35633107
[TBL] [Abstract][Full Text] [Related]
12. Plasma proteome alterations by MAPK inhibitors in BRAF
Babačić H; Eriksson H; Pernemalm M
Neoplasia; 2021 Aug; 23(8):783-791. PubMed ID: 34246984
[TBL] [Abstract][Full Text] [Related]
13. Defining the Molecular Genetics of Dermoscopic Naevus Patterns.
Tan JM; Tom LN; Soyer HP; Stark MS
Dermatology; 2019; 235(1):19-34. PubMed ID: 30332666
[TBL] [Abstract][Full Text] [Related]
14. Eruptive Melanocytic Nevi Secondary to Encorafenib for BRAF Mutant Metastatic Colorectal Cancer.
Meneguzzo A; Lazzarotto A; Alaibac M
In Vivo; 2020; 34(1):441-445. PubMed ID: 31882511
[TBL] [Abstract][Full Text] [Related]
15. Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases.
Green JS; Norris DA; Wisell J
Br J Dermatol; 2013 Jul; 169(1):172-6. PubMed ID: 23413975
[TBL] [Abstract][Full Text] [Related]
16. Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma.
Ramani NS; Curry JL; Kapil J; Rapini RP; Tetzlaff MT; Prieto VG; Torres-Cabala CA
Am J Dermatopathol; 2015 Aug; 37(8):e96-9. PubMed ID: 25839886
[TBL] [Abstract][Full Text] [Related]
17. Melanocytic naevi with globular and reticular dermoscopic patterns display distinct BRAF V600E expression profiles and histopathological patterns.
Marchetti MA; Kiuru MH; Busam KJ; Marghoob AA; Scope A; Dusza SW; Cordova MA; Fonseca M; Wu X; Halpern AC
Br J Dermatol; 2014 Nov; 171(5):1060-5. PubMed ID: 25039578
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
19. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
Kim A; Cohen MS
Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
[TBL] [Abstract][Full Text] [Related]
20. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
